You are here: Industry Insights > GC012F

News List

Research progress of dual-target CAR-T in China from the perspective of the ASCO 2023 Xiaobin/PharmaSources
June 27, 2023
At the ASCO this year, Gracell Bio announced the long-term follow-up data of its multi-center clinical study of CAR-T therapy with GC012F for recurrent/refractory multiple myeloma (R/R MM) in the form of oral report at the annual meeting.
Gracell Biotechnologies Granted FDA Orphan Drug Designation for FasTCAR-enabled BCMA/CD19 Dual-targeting CAR-T Cell Therapy Candidate GC012F for the Treatment of Multiple Myeloma prnasia
November 22, 2021
Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer...
Gracell Biotechnologies Announces Presentation of First-in-Human Data of GC012F a First-in-Class FasTCAR-enabled Dual-targeting BMCA/CD19 CAR-T Cell Therapy for Patients with Relapsed or Refractory Mu prnasia
December 07, 2020
Gracell Biotechnologies Inc., a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced an interim readout to evaluate the safety and efficacy of ...